Home › Lung Cancer › NCT03655015

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer (CTMS 18-0056)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure.
* Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care
* Any clinical stage of lung cancer
* Adult patients ≥18 years of age
* Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history

Exclusion Criteria:

* At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.

About the study

Create a living biobank of PDOs from Stage I-III lung cancer patients.

What is being tested

• Lung Tumor Resection (procedure)

Sponsor: The University of Texas Health Science Center at San Antonio · Participants: 150 · Started: Oct 16, 2018

Contact the study team

• Josephine Taverna, MD · Phone: 210-450-8234

Official record on ClinicalTrials.gov — NCT03655015

Locations in the U.S.

Conditions

• Lung Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.